Nicolas Solban

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

19h-index1.7kcitations71works9.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Photodynamic Therapy Research Studies(19), Nanoplatforms for cancer theranostics(18), Angiogenesis and VEGF in Cancer(13), TGF-β signaling in diseases(12), Cancer, Hypoxia, and Metabolism(10)

Publications71 total

Abstract 27: Orthotopic tumor models using luciferized patient-derived organoids for investigating EGFR-MAPK pathway inhibition in colorectal and pancreatic cancer
Cancer Research·2025
Abstract 22: Engineering KRAS-mutant-organoids from pancreatic ductal adenocarcinoma for advanced drug screening applications <i>in-vitro</i> and <i>in-vivo</i>
Cancer Research·2025
Discovery and Evaluation of TLR-Targeted Immune Agonists
Journal of Medicinal Chemistry·2024· 5 cited
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> Inhibitor
Journal of Medicinal Chemistry·2024· 31 cited
Abstract B074: Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor
Molecular Cancer Therapeutics·2023· 1 cited
Supplementary Figures S1-S2 from &lt;i&gt;In vivo&lt;/i&gt; Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment
2023Open Access
Data from &lt;i&gt;In vivo&lt;/i&gt; Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment
2023Open Access
Supplementary Table 1 from ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth
2023Open Access
Data from ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth
2023Open Access
Data from ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth
2023Open Access
Supplementary Table 1 from ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth
2023Open Access
Data from &lt;i&gt;In vivo&lt;/i&gt; Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment
2023Open Access
Supplementary Figures S1-S2 from &lt;i&gt;In vivo&lt;/i&gt; Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment
2023Open Access
Data from &lt;b&gt;&lt;i&gt;In Vivo&lt;/i&gt;&lt;/b&gt; Flow Cytometry
2023Open Access
Supplementary Material from &lt;b&gt;&lt;i&gt;In Vivo&lt;/i&gt;&lt;/b&gt; Flow Cytometry
2023Open Access
Supplementary Material from &lt;b&gt;&lt;i&gt;In Vivo&lt;/i&gt;&lt;/b&gt; Flow Cytometry
2023Open Access
Data from &lt;b&gt;&lt;i&gt;In Vivo&lt;/i&gt;&lt;/b&gt; Flow Cytometry
2023Open Access
Abstract 2455: Development of a bioluminescence reporter mouse model for tracking and quantifying Ly6G+ neutrophils in vivo
Cancer Research·2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing
Journal of Medicinal Chemistry·2022· 18 citedOpen Access
Sonoporation‐Enhanced Delivery of STING Agonist Induced Robust Immune Modulation and Tumor Regression (Adv. Therap. 10/2021)
Advanced Therapeutics·2021· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Tayyaba Hasan(18), R. Scott Pearsall(8), Imran Rizvi(8), Sung K. Chang(8), Ravindra Kumar(7), Yongxin Han(6), Brian J. Long(6), Jasbir Seehra(5), J. Richard Miller(5), David Jonathan Bennett(5), Pavel Hamet(5), Johanne Tremblay(5), Matthew L. Sherman(5), Aaron W. Mulivor(4), Kathryn Underwood(4), Asya V. Grinberg(4), Qinglin Pu(4), Hongjun Zhang(4), Xavier Fradera(4), Charles A. Lesburg(4)